Cardinal Health’s second quarter results reflected strong profit growth, despite revenue falling short of Wall Street’s expectations. Management credited broad-based demand in its Pharmaceutical and Specialty Solutions segment, stable operating margins, and continued progress on its improvement plan in the Global Medical Products and Distribution unit as key performance drivers. CFO Aaron Alt called out “strong demand, strong execution, strong profit,” highlighting the company’s ability to deliver high service levels and operational resilience even as regulatory and input cost pressures persisted.

Is now the time to buy CAH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Cardinal Health’s Q2 Earnings Call

• Erin Wilson Wright (Morgan Stanley): Asked how strong specialty growth and M&A impact guidance. CFO Aaron Alt said ongoing momentum in specialty and generics, plus M&A contributions, underpin expectations for continued profit growth.
• Elizabeth Anderson (Evercore ISI): Inquired about the sustainability of specialty segment growth and integration of new assets. CEO Jason Hollar emphasized ongoing double-digit specialty growth, especially in biopharma solutions and MSO services, with synergy realization from recent deals.
• Lisa Gill (JPMorgan): Sought details on regulatory changes (IRA, 340B) and their volume impact. Hollar explained that Cardinal Health’s role remains largely stable, and access-driven reforms could actually support volume expansion over time.
• Allen Lutz (BofA): Asked about the impact of brand-to-generic conversions on revenue and margin. Alt confirmed generics provided a positive margin lift, with further benefit expected in the coming quarters.
• Lucas Romanski (TD Cowen): Requested clarity on input cost pressures and progress of the GMPD recovery plan. Hollar detailed ongoing cost challenges but noted commercial flexibility and improved operational controls have made these headwinds more manageable.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be tracking (1) the pace of specialty and biopharma solutions growth, especially as newly integrated assets ramp up; (2) the impact of operational efficiency programs and automation on margins in the medical segment; and (3) the realization of synergy targets and profit improvement from at-Home Solutions and logistics. Updates on regulatory risk and input cost management will also be key signposts.

Cardinal Health currently trades at $234.73, down from $237.18 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.